All News

Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Results from the phase 2 CheckPAC trial indicated that stereotactic body radiotherapy plus nivolumab and ipilimumab produced a promising clinical benefit rate for patients with refractory metastatic pancreatic cancer.

Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.

Switch treatment with palbociclib and fulvestrant from aromatase inhibitors plus palbociclib upon onset of ESR1 blood mutations and before progression yielded better progression-free survival among those with estrogen receptor–positive, HER2-negative advanced breast cancer.

A meta-analysis found Black men who undergo radiotherapy for localized prostate cancer have better outcomes in terms of biochemical recurrence, distant metastases, and prostate cancer-specific mortality than White men despite presenting with more aggressive disease.

Data from the phase 1 LuMIERE study highlighted that targeted radiotherapy agent 177Lu-FAP-2286 demonstrated a manageable safety profile and promising preliminary antitumor activity.

Disease-free survival was not reached with perioperative nor adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer, although neoadjuvant chemotherapy yielded a numerical improvement in overall survival, according to data from the phase 2 NEONAX trial.

After a median of 50 months of follow-up, palbociclib plus adjuvant endocrine therapy did not improve invasive disease-free survival in a subgroup of patients with stage IIA estrogen receptor–positive breast cancer

Many communities face persistent and tenacious issues surrounding the treatment of patients with breast cancer, according to the founder of the Missing Pink Breast Cancer Alliance.

The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.

Tycel Phillips, MD, reviewed effective second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.

A panel of experts convened at the 2022 NCCN: Hematologic Malignancies Conference to discuss the classification, treatment options, and supportive care strategies available for patients with acute myeloid leukemia.

GPRC5D appears to be an active, promising target for CAR T-cell product MCARH109 in heavily pretreated multiple myeloma.

Results from a randomized controlled trial highlighted that the TissueCypher Barrett’s Esophagus Test heightened accuracy for assessing progression risk in high-grade dysplasia and esophageal adenocarcinoma among patients with Barrett’s esophagus.

As part of Breast Cancer Awareness Month, CancerNetwork® spoke with Deborah M. Axelrod, MD, about developments within the surgical breast cancer space, including decreasing the need for re-excision and full lymph node dissection.

Joseph Mikhael, MD, in a conversation on important presentations from the 2022 International Myeloma Society Annual Meeting, highlighted key findings with lenalidomide plus RVd and stem cell transplant in patients with high-risk multiple myeloma.

During Breast Cancer Awareness Month, CancerNetwork® spoke with Megan May, PharmD, about her role as a pharmacist on a multidisciplinary cancer care team.

Ritu Salani, MD, highlights key data from the 2022 ESMO Congress, including those surrounding PARP inhibitor maintenance in advanced ovarian cancer and the latest developments in immunotherapeutics for endometrial and cervical cancer.

Topline results from the phase 3 ALPINE trial’s final progression-free survival analysis highlighted that zanubrutinib yielded higher progression-free survival compared with ibrutinib in patients with chronic lymphocytic leukemia.

Lillian Gien, MD, spoke about continued use of immunotherapy in patients with recurrent clear cell carcinoma of the ovary following results of a trial examining pembrolizumab plus epacadostat.

Expert oncologists review clinical scenarios to define best treatment practices for patients with EGFR-mutated non–small cell lung cancer.

Centering discussion on two clinical scenarios, expert panelists review recent evolutions in the field of graft-vs-host disease management and provide their perspective on optimal treatment strategies.

Incorporating tumor grade and histology into an externally validated modified salivary gland staging system improved hazard discrimination in patient subgroups.

Phase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).

In a conversation during Hispanic Heritage Month, Ruben Mesa, MD, highlights factors that may contribute to disparities in clinical trial enrollment of Hispanic and Latinx patients with cancer and strategies that may encourage study participation.

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): a prospective phase 2/3 trial of MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches using ctDNA status as a surrogate for MRD status (NRG-GI008) (NCT05174169).

CancerNetwork® sat down with Ruben Mesa, MD, to discuss the disparities present in Hispanic and Latinx patients with cancer.

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

Michael Wang, MD, spoke about key data from the phase 3 SHINE trial which analyzed the use of first-line ibrutinib plus bendamustine and rituximab in older patients with mantle cell lymphoma.

Findings from a study examining the prognostic value of Nutritional Risk Index prior to hematopoietic stem cell transplant in patients with acute myeloid leukemia highlighted a need to consider other tools for assessing nutritional status among those undergoing transplant.